Should telehealth be specialized or one-stop shop? — with Varsha Rao

NurX CEO Varsha Rao joins host Jonah Comstock and MobiHealthNews Managing Editor Laura Lovett to discuss her telehealth company's journey from a laser focus on contraception to a broader play for women's (and men's) health that includes dermatology and migraines. Along the way, we also discuss broader trends in telehealth, challenges of femtech, and NurX's foray into COVID-19 testing.Talking points:NurX’s storyWhat does it mean to be a female-focused telehealth company?Following a patient through her lifelong patient journeyHow NurX got into home COVID testingDigital health companies as service companiesChallenges and advantages of a woman-led startupThings men don’t understand about contraceptionNurX’s roadmap for new products, and COVID’s effect on itShould telehealth be a one-stop shop?The advantages of asynchronous telemedicineDealing with stigma in healthcareThe future of digital health and telehealthNurX’s role in COVID-19 testingWhat’s next for NurX?Varsha’s advice for healthcare startupsMore about this episode:Nurx CEO on what's next for women's health in 2021Nurx sets sights on the migraine and headache spaceNurx collects another $22.5M for birth control & STI treatment deliveriesAt-home COVID-19 testing services pump the brakes after FDA warns of 'fraudulent' kitsEverlyWell, Nurx to release at-home COVID-19 test kits within a weekNurx gets another $52 million to deliver mail-order birth control, PrEP, STI test kitsNurx adds STI testing to its mail-order product suiteNurx gets $36M for telemedicine for birth control, adds Chelsea Clinton to boardNurx raises $5.3M for app-based birth control and PrEP service